#USA #oncology #Rochester #Indivumed #Wilmot Cancer Institute

A Groundbreaking Collaboration in Cancer Research

In a remarkable announcement made on December 10, 2025, Indivumed and the University of Rochester Medical Center's Wilmot Cancer Institute revealed their partnership dedicated to discovering innovative treatments in precision oncology. This collaboration seeks to address the urgent medical needs of cancer patients by focusing on the development of novel therapies.

Pioneering a Patient-Centric Approach

Indivumed, a recognized leader in biotechnology, is committed to enhancing cancer research through its proprietary platform that utilizes standardized tissue and clinical data. This framework not only ensures high quality and integrity of samples but also facilitates patient-centered drug development. By leveraging the abundant resources of the URMC, the partners aim to streamline the research process, minimizing sample ischemia time to below ten minutes. This improvement ensures the preservation of sample integrity crucial for meaningful research outputs.

Dr. Hartmut “Hucky” Land, Deputy Director of the Wilmot Cancer Institute, emphasized the significance of this collaboration, stating, “Having successfully worked with Indivumed before, we are excited to leverage their innovative approaches to both tissue and multi-omics data. This partnership will enhance our capabilities to identify new therapies and biomarkers, which are pivotal in facilitating better clinical decisions.”

Focus on High Medical Need Cancers

The joint research initiative will primarily focus on advanced stages of solid tumors, particularly high-need cancers including colorectal, pancreatic, lung, and breast cancers. Future expansion to other cancer types is anticipated as the collaboration progresses. Through this innovative partnership, both organizations aim to enrich existing research initiatives and offer valuable insights that can guide oncologists in making informed treatment decisions for patients.

The initiative’s emphasis on developing Patient-Derived Tumor Models (PDTMs) is particularly noteworthy. These models, derived from actual patient samples, will inform the entire drug discovery pipeline from identification and validation to compound screening and development.

Commitment to Precision Medicine

Hartmut Juhl, CEO of Indivumed, expressed enthusiasm about this strategic alignment which aims to expedite the identification of novel cancer therapies while adopting a patient-centered methodology. “With our advanced AI-driven analytical capabilities, we are on a mission to swiftly connect novel compounds with their therapeutic targets, ensuring timely access to groundbreaking treatments for patients.”

Moreover, this partnership integrates the Wilmot Cancer Institute into Indivumed’s established Global Clinical Network that includes numerous prestigious hospitals and leading oncological institutes across North America, Europe, and Asia. It stands as a testament to the preceding collaborations between Indivumed and the URMC that have already led to significant advances, including a recent publication introducing a new method for classifying distinct colon cancer types.

The Wilmot Cancer Institute’s Legacy

As an NCI-designated cancer center based in Rochester, New York, the Wilmot Cancer Institute has built a strong reputation for delivering comprehensive cancer care and leading research initiatives that cater to a diverse patient population. With a dedicated team of over 190 oncology physicians, more than 500 nurses, and 115 scientists, they investigate various aspects of cancer, striving to improve patient outcomes and advance the frontiers of oncological research.

Conclusion

The collaboration between Indivumed and the University of Rochester Medical Center marks a significant step forward in the realm of precision oncology. With a shared goal of bridging the gap between groundbreaking research and clinical practice, they aim to provide innovative therapeutic solutions that prioritize patient needs in the ever-evolving landscape of cancer treatment. As this partnership unfolds, the scientific community and patients alike can anticipate an array of promising developments in the quest for effective cancer therapies.